stockrow
Friday 6 November 2026
Export REGN’s income statement to Excel — free account
Regeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
905.02
2.12
+0.23%
Follow REGN
Alert me
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
8,605.20 | 9,012.50 | 10,844.80 | 7,742.30 | 5,694.70 | 3,587.00 | 3,214.30 | 2,809.90 | 1,409.50 | 1,038.68 |
Receivables |
5,741.10 | 6,211.90 | 5,667.30 | 5,328.70 | 6,036.50 | 4,114.70 | 2,785.60 | 2,243.20 | 1,974.30 | 1,611.62 |
Inventory |
3,200.80 | 3,087.30 | 2,580.50 | 2,401.90 | 1,951.30 | 1,916.60 | 1,415.50 | 1,151.20 | 726.10 | 399.36 |
Total current assets |
18,021.90 | 18,660.90 | 19,479.20 | 15,884.10 | 14,014.90 | 9,779.10 | 7,689.10 | 6,447.60 | 4,335.00 | 3,180.19 |
Property, Plant, Equpment (Net) |
5,120.40 | 4,599.70 | 4,146.40 | 3,763.00 | 3,482.20 | 3,221.60 | 2,890.40 | 2,575.80 | 2,358.60 | 2,083.42 |
Long-Term Investments |
10,260.60 | 8,900.10 | 5,396.50 | 6,591.80 | 6,838.00 | 3,135.60 | 3,256.80 | 1,755.00 | 1,486.50 | 864.26 |
Goodwill and Intangible Assets (Total) |
1,257.40 | 1,148.60 | 1,038.60 | 915.50 | 6.70 | — | — | — | — | — |
Long Term Assets (Tax, Deferred) |
4,077.20 | 3,314.10 | 2,575.40 | 1,723.70 | 876.90 | 858.90 | 824.20 | 828.70 | 506.30 | 825.30 |
Long-term assets (Other) |
1,821.20 | 1,136.00 | 444.10 | 336.40 | 216.10 | 168.10 | 144.70 | 127.40 | 77.90 | 20.29 |
Total non-current assets |
22,536.80 | 19,098.50 | 13,601.00 | 13,330.40 | 11,419.90 | 7,384.20 | 7,116.10 | 5,286.90 | 4,429.30 | 3,793.28 |
Total Assets |
40,558.70 | 37,759.40 | 33,080.20 | 29,214.50 | 25,434.80 | 17,163.30 | 14,805.20 | 11,734.50 | 8,764.30 | 6,973.47 |
Accounts Payable |
939.00 | 789.50 | 606.60 | 589.20 | 564.00 | 475.50 | 418.10 | 218.20 | 178.20 | 879.10 |
Current Part of Capital Lease |
— | — | — | 0.00 | 719.70 | 0.00 | 713.90 | — | — | 129.56 |
Current Revenue (Deferred) |
553.00 | 627.70 | 458.90 | 477.90 | 442.00 | 577.70 | 382.10 | 452.50 | 320.10 | 231.66 |
Other current liabilities |
2,876.40 | 2,527.10 | 2,357.90 | 2,074.20 | 2,206.80 | 1,644.20 | 1,296.40 | 772.10 | 637.20 | 1.18 |
Total current liabilities |
4,368.40 | 3,944.30 | 3,423.40 | 3,141.30 | 3,932.50 | 2,697.40 | 2,096.60 | 1,442.80 | 1,135.50 | 1,241.50 |
Long Term Debt (Total) |
2,705.90 | 2,704.40 | 2,702.90 | 2,701.40 | 1,980.00 | 2,695.70 | 713.90 | 708.50 | 703.50 | 351.57 |
Non-current Revenue (Deferred) |
208.70 | 185.70 | 126.70 | 69.80 | 73.30 | 57.80 | 105.30 | 464.20 | 629.20 | 830.77 |
Non-current Liabilities (Other) |
2,018.80 | 1,571.40 | 854.10 | 638.00 | 680.20 | 687.10 | 799.70 | 361.70 | 152.00 | 100.39 |
Total non-current liabilities |
4,933.40 | 4,461.50 | 3,683.70 | 3,409.20 | 2,733.50 | 3,440.60 | 1,618.90 | 1,534.40 | 1,484.70 | 1,282.73 |
Total liabilities |
9,301.80 | 8,405.80 | 7,107.10 | 6,550.50 | 6,666.00 | 6,138.00 | 3,715.50 | 2,977.20 | 2,620.20 | 2,524.22 |
Additional Paid In Capital |
13,995.00 | 12,855.90 | 11,354.00 | 9,949.30 | 8,087.50 | 6,716.20 | 4,428.60 | 3,911.60 | 3,512.90 | 3,029.99 |
Common Stock (Net) |
0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.11 |
Retained Earnings |
35,797.10 | 31,672.90 | 27,260.30 | 23,306.70 | 18,968.30 | 10,893.00 | 7,379.80 | 5,254.30 | 2,946.70 | 1,748.22 |
Treasury Stock |
18,612.80 | 15,167.40 | 12,560.40 | 10,353.30 | 8,260.90 | 6,613.30 | 739.90 | 396.40 | 316.20 | 316.24 |
Common Equity (Total) |
31,256.90 | 29,353.60 | 25,973.10 | 22,664.00 | 18,768.80 | 11,025.30 | 11,089.70 | 8,757.30 | 6,144.10 | 4,449.25 |
Shareholders Equity (Total) |
31,256.90 | 29,353.60 | 25,973.10 | 22,664.00 | 18,768.80 | 11,025.30 | 11,089.70 | 8,757.30 | 6,144.10 | 4,449.25 |
Shareholders Equity and Liabilities (Total) |
40,558.70 | 37,759.40 | 33,080.20 | 29,214.50 | 25,434.80 | 17,163.30 | 14,805.20 | 11,734.50 | 8,764.30 | 6,973.47 |
Shares (Common) |
105.70 | 109.60 | 109.40 | 109.60 | 108.60 | 106.95 | 110.28 | 109.01 | 107.62 | 106.01 |
Shareholders Equity (Tangible) |
29,999.50 | 28,205.00 | 24,934.50 | 21,748.50 | 18,762.10 | 11,025.30 | 11,089.70 | 8,757.30 | 6,144.10 | 4,449.25 |
Net Debt |
(5,899.30) | (6,308.10) | (8,141.90) | (5,040.90) | (3,714.70) | (891.30) | (2,500.40) | (2,101.40) | (706.00) | (687.11) |
Total Debt |
2,705.90 | 2,704.40 | 2,702.90 | 2,701.40 | 1,980.00 | 2,695.70 | 713.90 | 708.50 | 703.50 | 351.57 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026